Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

Our center plans to conduct a prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of neoadjuvant chemotherapy combined with Anlotinib and Benmelstobart in the treatment of HR+/HER2- breast cancer. The aim is to further explore the treatment strategy of chemotherapy de-escalation for patients with HR+/HER2- breast cancer, provide more treatment options for breast cancer patients, and offer a potential theoretical basis for the precision treatment of breast cancer.The primary study objective is to evaluate the pathologic complete response（PCR）and RCB0-1 ratio o

Trial Details

NCT ID

NCT06874933

Phase

PHASE2

Sponsor

First Affiliated Hospital of Zhejiang University

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

Neoadjuvant Chemotherapy in Combination with Anlotinib and Benmelstobart

Locations (sample)

Hangzhou, Zhejiang, China|30.29365,120.16142
Hangzhou, Zhejiang, China|30.29365,120.16142
Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

Female patients aged between 18 and 75 years old.
With an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
Patients with histologically or pathologically confirmed invasive ductal carcinoma of the breast, and simultaneously meeting the following conditions:
T1c (≥1 cm) - 4c N0-2; Histologically confirmed as grade 3 by the research center; Immunohistochemical staining results confirm ER+ (≥1%), HER2 neg…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →